MAZE

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Maze Therapeutics, Inc. Common Stock

NASDAQ | MAZE

28.61

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 14, 2025)

$525.32M

Market Cap

-

P/E Ratio

-0.42

EPS

$29.66

52 Week High

$6.71

52 Week Low

HEALTHCARE

Sector

MAZE Chart

Recent Chart
Price Action

MAZE Technicals

Tags:

MAZE Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $168M
Total Revenue $168M
Cost Of Revenue $3.3M
Costof Goods And Services Sold $3.3M
Operating Income $58M
Selling General And Administrative $26M
Research And Development $83M
Operating Expenses $110M
Investment Income Net -
Net Interest Income $4.7M
Interest Income $4.7M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.3M
Income Before Tax $53M
Income Tax Expense $1.2M
Interest And Debt Expense -
Net Income From Continuing Operations $52M
Comprehensive Income Net Of Tax -
Ebit $58M
Ebitda $61M
Net Income $52M

Revenue & Profitability

Earnings Performance

MAZE Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $241M
Total Current Assets $202M
Cash And Cash Equivalents At Carrying Value $197M
Cash And Short Term Investments $197M
Inventory -
Current Net Receivables -
Total Non Current Assets $39M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $4.9M
Other Non Current Assets -
Total Liabilities $552M
Total Current Liabilities $21M
Current Accounts Payable $1.9M
Deferred Revenue -
Current Debt -
Short Term Debt $9.3M
Total Non Current Liabilities $531M
Capital Lease Obligations $27M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $27M
Other Current Liabilities $9.5M
Other Non Current Liabilities $969K
Total Shareholder Equity -$311M
Treasury Stock -
Retained Earnings -$358M
Common Stock $2K
Common Stock Shares Outstanding $44M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $76M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3.3M
Capital Expenditures $1.1M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$1.1M
Cashflow From Financing $93M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $52M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $168M
Total Revenue $168M
Cost Of Revenue $3.3M
Costof Goods And Services Sold $3.3M
Operating Income $58M
Selling General And Administrative $26M
Research And Development $83M
Operating Expenses $110M
Investment Income Net -
Net Interest Income $4.7M
Interest Income $4.7M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.3M
Income Before Tax $53M
Income Tax Expense $1.2M
Interest And Debt Expense -
Net Income From Continuing Operations $52M
Comprehensive Income Net Of Tax -
Ebit $58M
Ebitda $61M
Net Income $52M

MAZE News

MAZE Profile

Maze Therapeutics, Inc. Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity. With its headquarters in South San Francisco, California, the company leverages cutting-edge genetic insights to drive its innovative therapeutic pipeline. As it advances its clinical programs, Maze aims to address significant unmet medical needs, positioning itself as a leader in the precision medicine landscape.

VHAI
+66.66%
$0.00
CGBS
-39.47%
$0.03
UGRO
+71.96%
$0.63
YYAI
-22.88%
$0.13
BITF
+1.66%
$5.48
BURU
-21.69%
$0.40
SSKN
+40.90%
$2.17
QBTS
+23.01%
$40.61
NVTS
+22.71%
$12.23
ITP
+19.97%
$0.31
AXDX
-61.36%
$0.03
NVDA
-3.28%
$182.13
LAES
+11.41%
$6.83
CAN
+13.81%
$1.73
RGTI
-2.66%
$53.44
DNN
+1.46%
$3.12
EDHL
+104.36%
$1.01
CRML
+15.76%
$26.94
BYND
-22.73%
$0.79
MP
+21.34%
$95.06
PLUG
+0.38%
$3.91
INTC
-5.83%
$35.04
IONQ
+16.19%
$82.09
MNTS
+30.76%
$1.87
KDLY
-1.56%
$0.85
IONZ
+12.17%
$2.58
NAK
+3.94%
$2.76
JDZG
+29.21%
$2.42
RMBL
+60.50%
$3.21
ERIC
+18.11%
$9.65
GPUS
-10.00%
$0.38
ADD
-25.47%
$0.05
NUAI
+41.06%
$3.31
SRM
+53.27%
$10.30
UAMY
+4.60%
$17.48
UUUU
+3.70%
$24.65
AMD
+1.83%
$220.40
F
+0.42%
$11.58
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
TSLA
-2.60%
$424.55
DVLT
+7.57%
$1.82
WLGS
-5.57%
$0.04
AREC
+34.05%
$6.67
ETHD
+11.40%
$3.70
TMQ
+10.62%
$6.56
ADAP
-16.93%
$0.14
ETWO
0.00%
$3.30
VZ
-0.25%
$39.75
USAR
-3.83%
$37.19
WULF
+8.50%
$15.19
AMC
-2.71%
$2.87
SOFI
-0.60%
$26.97
TLRY
-3.84%
$1.62
AFMD
-34.94%
$0.18
CIFR
+0.19%
$20.38
IREN
+2.54%
$65.77
BTBT
+3.75%
$4.15
RXRX
-4.09%
$5.30
WWR
+13.27%
$2.89
PLTR
+1.70%
$180.23
APLD
+5.70%
$36.19
ITUB
+1.62%
$6.87
OPI
-16.97%
$0.20
GWAV
+95.88%
$16.67
GWH
-9.09%
$8.22
ABAT
+5.90%
$9.76
KLG
-9.05%
$13.35
BMNR
-6.35%
$53.23
NIO
-4.28%
$6.87
AMZN
-1.55%
$216.65
GRYP
-10.38%
$1.38
SOUN
+3.78%
$19.86
ONDS
-6.61%
$10.09
MODV
-25.22%
$0.43
C
+2.31%
$96.10
ATXS
+39.61%
$11.82
MARA
+3.65%
$20.98
ACHR
-5.12%
$12.11
RGTZ
+4.40%
$9.71
ELAB
+65.64%
$8.63
RR
-3.56%
$6.22
BBD
+1.67%
$3.14
SNAP
0.00%
$8.05
FNB
+2.35%
$15.62
CLSK
+6.21%
$21.28
QS
-1.58%
$16.72
BTG
+0.84%
$5.35
BMY
-0.95%
$43.54
NOK
+2.95%
$5.40
GRAB
+0.33%
$5.95
ASST
-5.54%
$1.02
PFE
-0.24%
$24.66
EXK
+10.96%
$8.50
ELBM
-31.39%
$4.81
TBH
-48.33%
$1.24
CLF
-1.15%
$13.67
REKR
+23.79%
$2.57
DFLI
-1.68%
$1.54
VHAI
+66.66%
$0.00
CGBS
-39.47%
$0.03
UGRO
+71.96%
$0.63
YYAI
-22.88%
$0.13
BITF
+1.66%
$5.48
BURU
-21.69%
$0.40
SSKN
+40.90%
$2.17
QBTS
+23.01%
$40.61
NVTS
+22.71%
$12.23
ITP
+19.97%
$0.31
AXDX
-61.36%
$0.03
NVDA
-3.28%
$182.13
LAES
+11.41%
$6.83
CAN
+13.81%
$1.73
RGTI
-2.66%
$53.44
DNN
+1.46%
$3.12
EDHL
+104.36%
$1.01
CRML
+15.76%
$26.94
BYND
-22.73%
$0.79
MP
+21.34%
$95.06
PLUG
+0.38%
$3.91
INTC
-5.83%
$35.04
IONQ
+16.19%
$82.09
MNTS
+30.76%
$1.87
KDLY
-1.56%
$0.85
IONZ
+12.17%
$2.58
NAK
+3.94%
$2.76
JDZG
+29.21%
$2.42
RMBL
+60.50%
$3.21
ERIC
+18.11%
$9.65
GPUS
-10.00%
$0.38
ADD
-25.47%
$0.05
NUAI
+41.06%
$3.31
SRM
+53.27%
$10.30
UAMY
+4.60%
$17.48
UUUU
+3.70%
$24.65
AMD
+1.83%
$220.40
F
+0.42%
$11.58
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
TSLA
-2.60%
$424.55
DVLT
+7.57%
$1.82
WLGS
-5.57%
$0.04
AREC
+34.05%
$6.67
ETHD
+11.40%
$3.70
TMQ
+10.62%
$6.56
ADAP
-16.93%
$0.14
ETWO
0.00%
$3.30
VZ
-0.25%
$39.75
USAR
-3.83%
$37.19
WULF
+8.50%
$15.19
AMC
-2.71%
$2.87
SOFI
-0.60%
$26.97
TLRY
-3.84%
$1.62
AFMD
-34.94%
$0.18
CIFR
+0.19%
$20.38
IREN
+2.54%
$65.77
BTBT
+3.75%
$4.15
RXRX
-4.09%
$5.30
WWR
+13.27%
$2.89
PLTR
+1.70%
$180.23
APLD
+5.70%
$36.19
ITUB
+1.62%
$6.87
OPI
-16.97%
$0.20
GWAV
+95.88%
$16.67
GWH
-9.09%
$8.22
ABAT
+5.90%
$9.76
KLG
-9.05%
$13.35
BMNR
-6.35%
$53.23
NIO
-4.28%
$6.87
AMZN
-1.55%
$216.65
GRYP
-10.38%
$1.38
SOUN
+3.78%
$19.86
ONDS
-6.61%
$10.09
MODV
-25.22%
$0.43
C
+2.31%
$96.10
ATXS
+39.61%
$11.82
MARA
+3.65%
$20.98
ACHR
-5.12%
$12.11
RGTZ
+4.40%
$9.71
ELAB
+65.64%
$8.63
RR
-3.56%
$6.22
BBD
+1.67%
$3.14
SNAP
0.00%
$8.05
FNB
+2.35%
$15.62
CLSK
+6.21%
$21.28
QS
-1.58%
$16.72
BTG
+0.84%
$5.35
BMY
-0.95%
$43.54
NOK
+2.95%
$5.40
GRAB
+0.33%
$5.95
ASST
-5.54%
$1.02
PFE
-0.24%
$24.66
EXK
+10.96%
$8.50
ELBM
-31.39%
$4.81
TBH
-48.33%
$1.24
CLF
-1.15%
$13.67
REKR
+23.79%
$2.57
DFLI
-1.68%
$1.54
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.